Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Human Genome Sciences CEO Is Former TAP President Thomas Watkins

This article was originally published in The Pink Sheet Daily

Executive Summary

Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.

You may also be interested in...

GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon

The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.

Human Genome Sciences Names Chairman

Argeris Karabelis, PhD, will become chairman of Human Genome Sciences' board of directors effective Oct. 17

TAP President Will Be Former Sales VP Alan MacKenzie

MacKenzie is rejoining TAP two months after being acquitted on charges of conspiracy to pay kickbacks to prescribers and defraud Medicaid in the U.S. government's investigation into Lupron marketing. Upon expiry of his term, current TAP President Thomas Watkins will rejoin Abbott in a senior management role.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts